E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Aspirin-Exacerbated Respiratory Disease (AERD) in patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) |
|
E.1.1.1 | Medical condition in easily understood language |
Patients with chronic rhinosinusitis with nasal polyps, suffering from Aspirin Induced Asthma (AIA) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 25.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10075084 |
E.1.2 | Term | Aspirin-exacerbated respiratory disease |
E.1.2 | System Organ Class | 100000004855 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
(1) Effect of nasal ATAD with lysine-aspirin on patient reported outcomes: - Rhinosinusitis and Asthma severity Visual analogue scale (VAS) - Nasal Congestion/Obstruction (NC) score - Short version of the Olfactory Disorders-Negative Statements (sQODNS) - Asthma control, measured with the Asthma Control Questionnaire (ACQ-6); - Health-related quality of life, using disease-specific health-related quality of life score, such as the Sino-Nasal Outcome Test-22 (SNOT-22) and the Standardised Asthma Quality of Life Questionnaire (AQLQ (S)); - Patient recognition of improvement: Patient Global Impression of Change (PGIC). - EQ-5D-5L to describe and value health (2)Incidence of significant serious and non-serious adverse events related to gastro-intestinal disturbance (nausea, vomiting, diarrhoea, abdominal pain). (3) Effect of nasal ATAD on provoking dose during nasal lysine-aspirin provocation test
|
|
E.2.2 | Secondary objectives of the trial |
(1) Effect of nasal lysine-aspirin on upper and lower airway: - Peak Nasal Inspiratory Flow (PNIF), - Smell score (UPSIT), - Forced Expiratory Volume in 1 second (FEV1), - Bronchial and nasal inflammation (Fractional exhaled NO (FeNO) and nasal NO (nNO). (2) Effect of nasal lysine-aspirin on polyp growth: - Nasal Polyp Score (NPS), - The ability in reducing the proportion of patients who require surgery for nasal poyps (NP) (3) Effect of nasal lysine-aspirin on corticosteroid use: - The ability in reducing the proportion of patients who require treatment with oral corticosteroids (OCS) for relief of chronic rhinosinusitis and asthma exacerbations. - Changes in dosage of inhaled/intranasal corticosteroids)
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Patient has N-ERD: intolerance to aspirin is confirmed by a nasal lysine-aspirin provocation test in the pre-trial S65796 (EUDRACT: 2022-000215-31) - Patients older than 18 years.
|
|
E.4 | Principal exclusion criteria |
- Female who is pregnant or breast-feeding. - Participants with severe gastro-intestinal disease or with bleeding diathesis. - Participants with chronic urticaria. - Participants with unstable cardiovascular conditions/cardiopulmonary disease where epinephrine is contraindicated. - Participants with severe chronic obstructive pulmonary disease (COPD). - Participants with poorly controlled asthma, defined as: a. FEV1 < 65 % predicted while on preventative inhalers b. Participants who experienced an asthma exacerbation requiring hospitalization (>24 hours) for treatment of asthma within 3 months before screening - Participants who have undergone any intranasal and/or sinus surgery (including polypectomy) within 2 months before screening. - Participants with major anatomical nasal abnormalities or conditions/concomitant diseases being responsible for nasal obstruction and making them nonevaluable at screening, but not limited to: antrochoanal polyps, nasal septal deviation that would occlude at least one nostril, acute sinusitis, nasal infection or upper respiratory infection requiring treament with systemic antibiotics, antivirals or antifungals, ongoing rhinitis medicamentosa, fungal rhinosinusitis. - Participants who have taken biologic therapy within 3 months prior to screening or 5 half-lives, whichever is longer |
|
E.5 End points |
E.5.1 | Primary end point(s) |
- Change from baseline in VAS for rhinosinusitis and asthma severity - Change from baseline in NC score - Change from baseline in ACQ-6 score - Change from baseline in SNOT-22 score - Change from baseline in AQLQ(S) - Change from baseline in PGIC - Change from baseline in sQODNS score - Change from baseline in EQ-5D-5L - Change from baseline in provoking dose
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
- Change from baseline in PNIF - Change from baseline in smell score (UPSIT) - Change from baseline in FEV1 - Change from baseline in FeNO and nNO - Change from baseline in NPS - Proportion of patients who have or are planned for surgery of nasal polyps, as well as time-to-event - Proportion of patients with OCS use for chronic rhinosinusitis/asthma exacerbation, as well as time to first course, number of courses, total dose used, total duration. - Dosage (dose and frequency) of inhaled/intranasal corticosteroids, reported as dosage during desensitisation and dosage during maintenance therapy (after goal of escalation is reached).
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |